References
- 1. Ahn D-G, Shin H-J, Kim M-H, Lee S, Kim H-S, Myoung J, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). Journal of Microbiolog and Biotechnology. 2020;30(3): 313–324.10.4014/jmb.2003.03011
- 2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 Novel Coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395: 565–74.10.1016/S0140-6736(20)30251-8
- 3. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2): 281–292.e6.10.1016/j.cell.2020.02.058
- 4. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to understanding the 2019 novel coronavirus. Mayo Clinic Proceedings. 2020;95: 646–652.10.1016/j.mayocp.2020.02.003
- 5. Lee VJ, Ho ZJM, Goh EH, Campbell H, Cohen C, et al.; WHO working group on influenza burden of Disease. Advances in measuring influenza burden of disease. Influenza and Other Respiratory Viruses. 2018;12: 3–9.10.1111/irv.12533
- 6. Who.int. 2021. Up to 650 000 people die of respiratory diseases linked to seasonal flu each year. [online] Available at: https://www.who.int/news/item/13-12-2017-up-to-650-000-people-dieof-respiratory-diseases-linked-to-seasonal-flu-each-year.
- 7. CDC (Center for Disease Control and Prevention). Influenza Type A Viruses; 2017b. https://www.cdc.gov/flu/avianflu/influenza-a-virus-subtypes.htm.
- 8. World Health Organization. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus2019 [Accessed 25th October 2020].
- 9. Similarities and Differences between Flu and COVID-19. Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/flu/symptoms/flu-vs-COVID-19.htm. [Accessed 16th November 2020].
- 10. Wang M, Wu Q, Xu W, Qiao B, Wang J, Zheng H, et al. Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. Medrxiv; Februay 2020. doi:10.1101/2020.02.12.200 22327.
- 11. Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emergency Infectious Diseases. 2020;26(6): 1324–1326.10.3201/eid2606.200299
- 12. Payan EC, Montagud-Marrahi E, Torres-Elorza M, Bodro M, Blasco M, Poch E, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020;395(10236): e84.10.1016/S0140-6736(20)31052-7
- 13. Khodamoradi Z, Moghadami M, Lotfi M. Co-infection of corona-virus disease 2019 and influenza A: a report from Iran. Archives of Iranian Medicine. 2020;23(4): 239–243.10.34172/aim.2020.0432271596
- 14. Ma S, Lai X, Chen Z, Tu S, Qin K. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. International Journal of Infectious Diseases. 2020;96: 683–687.10.1016/j.ijid.2020.05.068725007232470606
- 15. Xing Q-S, Li G-J, Xing Y-H, Chen T, Li W-J, Ni W, et al. Precautions are Needed for COVID-19 patients with coinfection of common respiratory pathogens. 2020; doi:10.1101/2020.02.29.2002 7698.
- 16. Singh B, Kaur P, Reid RJ, Shamoon F, Bikkina M. COVID-19 and influenza co-infection: report of three cases. Cureus. 2020;12(8): e9852.10.7759/cureus.9852743709832832306
- 17. Gostin L, Salmon D. The dual epidemics of COVID-19 and influenza. Published Online: June 11, 2020. doi:10.1001/jama.2020.10802.10.1001/jama.2020.10802
- 18. People at High Risk of Flu. Centers for disease control and prevention; 2020. Available from: https://www.cdc.gov/flu/highrisk/index.htm. [Accessed 16th November 2020].
- 19. Eldanasory OA, Rabaan AA, Al-Tawfiq JA. Can influenza vaccine modify COVID-19 clinical course? Travel Medicine and Infectious Disease. 2020;37: 101872.
- 20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395: 1054–1062.10.1016/S0140-6736(20)30566-3
- 21. Behrouzi B, Araujo Campoverde M, Liang K, Talbot HK, Bogoch II, McGeer A, et al. Influenza vaccination to reduce cardiovascular morbidity and mortality in patients with COVID-19. Journal of the American College of Cardiology. 2020;76(15): 1777–1794.10.1016/j.jacc.2020.08.028753580933032740
- 22. Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza vaccination and COVID-19 mortality in the USA. MedRxiv 2020;2020. doi:10.1101/2020.06.24.201 29817. 06.24.20129817.
- 23. Marín-Hernández D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher influenza vaccine up-take in the elderly and lower COVID-19 deaths in Italy [published online ahead of print, 2020 Jun 4]. Journal of Medical Virology. 2020; doi:10.1002/jmv.26120.10.1002/jmv.26120730099532497290
- 24. Blank P, Szucs T. Increasing influenza vaccination coverage in recommended population groups in Europe. Expert Review of Vaccines, 2009;8(4): 425–433.10.1586/erv.09.719348558
- 25. Ecarnot F, Maggi S, Michel JP. Strategies to Improve Vaccine Uptake throughout Adulthood. Interdiscip Top Gerontol Geriatr. 2020;43:234-248. doi: 10.1159/000504486. PMID: 32305979.10.1159/00050448632305979
- 26. Sheikh S, Biundo E, Courcier S, Damm O, Launay O, Maes E, et al. A report on the status of vaccination in Europe. Vaccine. 2018;36(33): 4979–4992.10.1016/j.vaccine.2018.06.04430037416
- 27. Doherty M, Schmidt-Ott R, Santos J, Stanberry L, Hofstetter A, Rosenthal S, et al. Vaccination of special populations: protecting the vulnerable. Vaccine. 2016;34(52): 6681–6690.10.1016/j.vaccine.2016.11.01527876197
- 28. Lu P, O’Halloran A, Ding H, Srivastav A, Williams W. Uptake of influenza vaccination and missed opportunities among adults with high-risk conditions, United States, 2013. The American Journal of Medicine. 2016;129(6): 636.e1–636.e11.10.1016/j.amjmed.2015.10.031583107826551981
- 29. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O’Leary ST, Omer SB. Enhancing uptake of influenza maternal vaccine. Expert Review of Vaccines. 2018; doi:10.1080/14760 584.2019.1562907.
- 30. To K, Lai A, Lee K, Koh D, Lee S. Increasing the coverage of influenza vaccination in healthcare workers: review of challenges and solutions. Journal of Hospital Infection. 2016;94(2): 133–142.10.1016/j.jhin.2016.07.00327546456
- 31. Zeng Q, Langereis MA, van Vliet ALW, Huizinga EG, de Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proceedings of the National Academy of Sciences of the USA. 2008;105(26): 9065–9069.10.1073/pnas.0800502105244936518550812
- 32. Abdella R, Aggarwal M, Okura T, Lamb RA, He Y. Structure of a paramyxovirus polymerase complex reveals a unique methyltransferase-CTD conformation. Proceedings of the National Academy of Sciences of the USA 2020;117(9): 4931–4941.10.1073/pnas.1919837117706069932075920
- 33. Khorramdelazad H, Kazemi MH, Najafi A, Keykhaee M, Emameh RZ, Falak R. Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of co-infection. Microbial Pathogenesis. 2021;152: 104554.10.1016/j.micpath.2020.104554760723533157216
- 34. Stegemann-Koniszewski S, Behrens S, Boehme JD, Hochnadel I, Riese P, Guzmán CA, et al. Respiratory influenza A virus infection triggers local and systemic natural killer cell activation via toll-like receptor 7. Frontiers in Immunology. 2018;9: 245.10.3389/fimmu.2018.00245581957629497422
- 35. Poulas K, Farsalinos K, Zanidis C. Activation of TLR7 and innate immunity as an efficient method against COVID-19 pandemic: imiquimod as a potential therapy. Frontiers in Immunology. 2020;11. doi:10.3389/fimmu.2020.01373.10.3389/fimmu.2020.01373730757232612613
- 36. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Review in Vaccines. 2012;11: 985–994.10.1586/erv.12.61351450623002979
- 37. Jehi L, Ji X, Milinovich A, Erzurum S, Rubin B, Gordon S, et al. Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients. Chest. 2020; doi:10.1016/j. chest.2020.05.580.
- 38. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. 2020;26: 453–455.10.1038/s41591-020-0819-2709503632284614
- 39. Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roksin KM, et al. Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. Nature Immunology. 2016;17: 1226–1234.10.1038/ni.3533505497927525369
- 40. Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nüssing S, et al. Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Science Translational Medicine. 2018;10(428): 1–15.10.1126/scitranslmed.aan840529444980
- 41. Gould V, Francis JN, Anderson KJ, Georges B, Cope AV, Tregoning JS. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Frontiers in Microbiology, 2017;8: 900.10.3389/fmicb.2017.00900543414428567036
- 42. Varadhachary A, Chatterjee D, Garza J, Garr RP, Foley C, Letkeman AF, et al. Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity against COVID-19. medRxiv [Preprint]. 2020 Aug 11:2020.08.07.20170258. doi: 10.1101/2020.08.07.20170258. PMID: 32817976; PMCID: PMC7430621.10.1101/2020.08.07.20170258743062132817976
- 43. Debisarun P, Struycken P, Domínguez-Andrés J, et al. The effect of influenza vaccination on trained immunity: impact on COVID-19. MedRXiv. doi:10.1101/2020.10.14.20212498.10.1101/2020.10.14.20212498
- 44. Horns F, Dekker LC, Quake SR. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Reports. 2020;30: 905–913.10.1016/j.celrep.2019.12.063789155631968262
- 45. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer AP, Daubenberger C, et al. Inactivated trivalent influenza vaccine is associated with lower mortality among COVID-19 patients in Brazil. n.d.; doi:10.1101/2020.06.29.20142505.10.1101/2020.06.29.20142505
- 46. Salem ML, El-Hennawy D. The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19 [published online ahead of print, 2020 Apr 22]. Medical Hypotheses. 2020;140: 109752.10.1016/j.mehy.2020.109752719494332361099
- 47. Li Q, Tang B, Bragazzi NL, Xiao Y, Wu J. Modeling the impact of mass influenza vaccination and public health interventions on COVID-19 epidemics with limited detection capacity. Mathematical Biosciences. 2020;325: 108378.10.1016/j.mbs.2020.108378722976432507746
- 48. Maltezou HC, Theodoridou K, Poland G. Influenza immunization and COVID-19. Vaccine. 2020;38(39): 6078–6079. doi:10.1016/j.vaccine.2020.07.058.10.1016/j.vaccine.2020.07.058738878032773245
- 49. Grech V, Borg M. Influenza vaccination in the COVID-19 era. Early Human Development. 2020; doi:10.1016/j.earlhumdev.2020.105116.10.1016/j.earlhumdev.2020.105116730181632604011
- 50. Thindwa D, Garcia Quesada M, Liu Y, Bennett J, Cohen C, Knoll MD, et al. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine. 2020;38(34): 5398–5401.10.1016/j.vaccine.2020.06.047730365932600911
- 51. Paget J, Caini S, Cowling B, Esposito S, Falsey AR, Gentile A, et al. The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine. 2020;38(42): 6485–6486.10.1016/j.vaccine.2020.08.024743756532859436